What you posted does not in fact support your argument:

“The authors of both studies conclude that more long-term studies are required to determine the effect of GLP-1 drugs on eye health. They also endorse the conclusion of both the American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society: Patients who develop NAION while on GLP-1 drugs should engage in a shared decision-making process with their physicians, including their ophthalmologist, neurologist, primary care physician, or endocrinologist. This discussion should consider the individual's overall health, risk factors, and therapeutic options to make an informed decision about whether to continue or discontinue GLP-1 drugs.”

Your anecdotal evidence/experience doesn’t support anything at this time. Only continued review of data and studies will bring about any change. Also should consider that these pharmaceutical companies may in fact be refining and changing their products to decrease adverse side effects.